Overview

Long Term Safety of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease

Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
This was an open-label study to provide an opportunity for participants with Ulcerative Colitis (UC) who previously completed Study C13002 (NCT01177228), and for treatment-naïve participants with UC or Crohn's Disease (CD) to receive treatment with vedolizumab, and to determine the long term safety of vedolizumab in patients afflicted with these diseases.
Phase:
Phase 2
Details
Lead Sponsor:
Millennium Pharmaceuticals, Inc.
Treatments:
Vedolizumab